Related Experiment Videos
[First somatic human gene therapy in the USA approved]
Diskussionsforum Medizinische Ethik
|September 1, 1990
Summary
Gene therapy is now approved for infants with adenosine deaminase (ADA) deficiency, a severe combined immunodeficiency. This marks a significant milestone as the first federally approved somatic gene therapy.
Area of Science:
- Immunology
- Genetics
- Biotechnology
Context:
- Severe combined immunodeficiency (SCID) is a group of rare genetic disorders.
- Adenosine deaminase (ADA) deficiency is a specific cause of SCID, leading to a severely compromised immune system.
- Gene therapy offers a potential treatment for genetic disorders by modifying a patient's genes.
Purpose:
- To outline the approval of a clinical protocol for gene therapy in infants with ADA-SCID.
- To highlight the regulatory review process and its outcome.
Summary:
- A clinical protocol for treating infants with ADA-SCID using gene therapy has received approval.
- The Human Gene Therapy Subcommittee and RAC at NIH completed their review on July 30th.
- This approval signifies the commencement of the first federally sanctioned somatic gene therapy trial.
Impact:
- Paves the way for innovative treatments for primary immunodeficiencies.
- Represents a critical advancement in the field of human gene therapy.
- Offers hope for infants diagnosed with ADA-SCID and potentially other genetic disorders.